The Pharma and Biotech sectors are at a pivotal point in their evolution. Pharmaceutical companies are likely to continue to increase the percentage of their R&D work that is outsourced in Asia. This trend will continue to be driven by the pursuit of Open Innovation in University-Industrial Partnership, Improving R&D cost efficiency as well as effectiveness. Beyond generating one-off savings, the emphasis will move to streamlining theoutsourcing operating model, risk management, complexity management and lean process improvement. Doing more R&D with less and smartly.

The Asia Pharma R&D Leaders Summit 2017 ( APRDL 2017 )will bring in fresh perspectives and scientific advancement on popular therapeutic areas inNeurodegenerative Diseases; Cancer, Diabetes and metabolic diseaseswhich big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, Precision Medicine, IP management and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2017 – the most premier pharma R&D event in China with Asia perspectives: With over 50 speakers and estimation to bring over 250 pharma R&D professionals, the key conference topics will cover: -- Asian Strategies: How Big Pharma and Biotech companies manage their R&D activities -- How can companies drive maximum value from M&A and licensing deals -- Government initiatives in China 13th 5 years’ plan benefit for your research projects in China -- Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order -- Novel Technologies and Approaches for Drug Discovery -- Precision Medicine & Personalized Healthcare -- Research Ethics & Ethical Approval -- Develop new business models in 2017 and beyond for pharma R&D geared toward cost efficiency and ROI improvement -- Navigate Asia market trends for heavily invested therapeutics areas: Oncology, Neurodegenerative and metabolic diseases -- Lay foundations for effective partnership with top CROs, Biotech and Academia -- Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia -- Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process -- Open Innovation in University-Industrial Partnership for BioMedical Technology Development -- Personalized anticancer drug discovery & development in Asia On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests And the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and cozy, guided networking sessions for all professionals and management who are working for the pharmaceutical research and development programs in Asia.

Day1TUESDAYMarch21,2017

08:40 大会主席开幕致辞

加强并优化亚太药物研发合作创新

08:50 全球药物研发领袖圆桌讨论：未来5年全球制药企业在中 国的投入与合作创新

这场全球药物研发领袖圆桌旨在探讨未来中国的药物研发创新；我们邀请全球药物研发领袖(来自跨国药厂全球总部的战略决策层)参与圆桌讨论并且分享他们未来在中国的研发投入和战略合作发展

主持嘉宾

TobiasGabriel,

全球化学药物研发创新副总裁, 诺华全球生物医学研究中心（瑞士总部）

Panelists:

UweSchoenbeck,

全球药物研发外部创新合作高级副总裁,辉瑞全球研发首席科学官 –辉瑞制药 ( 美国总部)

Joern-PeterHalle

全球高级副总裁，研发创新负责人, 默克生物制药 ( 德国总部 )

SorenTullin,

诺和诺德生物化学技术集团副总裁 ( 丹麦总部 )

BenjaminSeet

生物药品委员会执行总监, 新加坡 A*Star – ( 新加坡总部 )

MikeDethick

董事总经理, 中国外商投资企业协会药品研制和开发行业委员会 – ( 中国总部 )

利民,

葛兰素史克中国研发中心总经理及全球神经系统药物研发部总裁 –全球部门总裁级别，中国研发中心总经理

陈东敏

院長／部長／講席教授; 北京大學產業技術研究院 ｜ 北京大學科技開發部 ｜ 北京大學前沿交叉學科研究院

09:40 区域药物研发领袖圆桌讨论：促进中国与亚太研发创新 -- 从跨国药厂亚太药物研发领袖；本土药厂的研发决策层和研发外包组织的视角讨论未来药企在中国的创新与合作

Moderator:

李建昌，总经理，桑迪亚医药技术 （上海）有限责任公司

严伟翠，董事长，桑迪亚医药技术 （上海）有限责任公司

Panelists:

牟骅,

首席科学官，集团研发总裁, 先声药业

倪彬晖,

副总裁, 全球研发战略, 亚洲/太平洋地区负责人，赛诺菲

TomKinzel,

拜尔中国药物研发创新中心总裁

李彬,

亚太和日本研发与合作总监，Abbvie

章蓓,

礼来中国研发有限公司总经理，礼来全球研发副总裁, 礼来制药

石斌,

外部研发合作与创新总监，安进亚太药物研发中心

夏明德,

高级总监，强生亚太创新中心

GregoryFanning,

总裁, 强生中国研发中心

10:10 通过整体的测试平台来加速药物研发 ( 药明康德 赞助 )

10:40茶歇，展台访问与交流

11:10通过并优化全球的战略合作与投资，加速药物研发创新

UweSchoenbeck,

全球药物研发外部创新合作高级副总裁, 辉瑞全球研发首席科学官

– 辉瑞制药 ( 美国总部)

11:40 Singapore A*Star:研发和技术企业在开放式创新中扮演的角色

BenjaminSeet

生物药品委员会执行总监, 新加坡 A*Star

开放式创新与合作机遇

13:30学术机构与跨国制药企业的合作：从全球的视角看亚太区域的合作创新机遇

利民,

葛兰素史克中国研发中心总经理及全球神经系统药物研发部总裁 –

全球部门总裁级别，中国研发中心总经理

14:00通过大学与制药企业的开放式创新合作来加速生物医疗技术的发展

陳東敏

院長／部長／講席教授; 北京大學產業技術研究院 ｜ 北京大學科技 開發部 ｜ 北京大學前沿交叉學科研究院

14:30将最高精尖的科学带到中国– 从跨国药厂的角度谈第十三个

五年计划内的中国药物创新和投资机遇

石斌,

外部研发合作与创新总监，安进亚太药物研发中心

15:00茶歇，展台访问与交流

糖尿病的新药开发与治疗

15:30 研究并且评估多肽和蛋白对二型糖尿病的治疗 Soren Tullin, 诺和诺德生物化学技术集团副总裁(丹麦总部)

16:00 结合灵长类动物的糖尿病模型应用于新型药物的研究

汪亦欣, 心血管和代谢疾病部高级副总裁，冠科医药

16:30 在亚太进行药物和医疗器械临床试验的挑战

Timothy Low, 首席执行官，新加坡FARRERPARKHOSPITAL

17:00 第一天会议结束 日程及嘉宾详见网址：http://www.huodongjia.com/event-839385283.html